Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Catalyst Pharmaceuticals Inc CPRX

Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for... see more

Recent & Breaking News (NDAQ:CPRX)

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire 2 days ago

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work

GlobeNewswire 8 days ago

Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 6, 2024

Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024

GlobeNewswire October 22, 2024

Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts

GlobeNewswire October 8, 2024

Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024

GlobeNewswire October 1, 2024

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan

GlobeNewswire September 24, 2024

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire August 20, 2024

Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 7, 2024

Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada

GlobeNewswire July 24, 2024

Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024

GlobeNewswire July 22, 2024

Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®

GlobeNewswire May 30, 2024

Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024

GlobeNewswire May 28, 2024

Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 8, 2024

Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024

GlobeNewswire May 1, 2024

Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024

GlobeNewswire April 22, 2024

Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day

GlobeNewswire March 28, 2024

Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

GlobeNewswire March 27, 2024

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

GlobeNewswire March 13, 2024

Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference

GlobeNewswire March 5, 2024